Management lifted FY guidance after another strong quarter. Sales weakened 1% to €11,883m (volumes: +4%; prices: -2%; FX: -4%) in Q2, but the gross profit margin improved further (57.5% after 56.1%). EBITDA grew +12% to €2,952m and net profit attributable to shareholders rose +19% to €1,448m. Despite the stronger operating performance, operating CF stood fairly unchanged at €1,982m as NWC outflow strongly moved up from €-205m to €-374m, hit by significantly highe
28 Jul 2016
Pharmaceuticals made the pace
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pharmaceuticals made the pace
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
28 Jul 2016 -
Author:
Martin Schnee -
Pages:
3
Management lifted FY guidance after another strong quarter. Sales weakened 1% to €11,883m (volumes: +4%; prices: -2%; FX: -4%) in Q2, but the gross profit margin improved further (57.5% after 56.1%). EBITDA grew +12% to €2,952m and net profit attributable to shareholders rose +19% to €1,448m. Despite the stronger operating performance, operating CF stood fairly unchanged at €1,982m as NWC outflow strongly moved up from €-205m to €-374m, hit by significantly highe